Silke Hoersch

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

Véronique Dièras, David Miles, Sunil Verma et al. · The Lancet Oncology · 2017 · 656 citations

Medicine, Oncology, Pharmacology +17

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n et al. · The Lancet Oncology · 2017 · 523 citations

Medicine, Oncology, Pharmacotherapy +17

Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure

Franz Hartmann, Milton Packer, Andrew J.S. Coats et al. · Circulation · 2004 · 302 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial

Hans‐Joachim Schmoll, Josep Tabernero, Jean A. Maroun et al. · Journal of Clinical Oncology · 2015 · 302 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

Edith A. Perez, Carlos H. Barrios, W. Eiermann et al. · Cancer · 2019 · 114 citations · Full text

Medicine, Oncology, Pharmacology +17